Johnson & Johnson stock gets deeper prostate-cancer response signal
Published on 11/10/2026 at 16:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEarly Data Support Phase 3
- Johnson & Johnson reported that 11 of 15 patients achieved at least a 50 percent PSA reduction in the Phase 1 study.
- The pasritamig and JNJ-9401 combination is advancing into a Phase 3 trial for metastatic castration-resistant prostate cancer.
- The preliminary findings come from a small, heavily pretreated patient group and require confirmation in larger studies.
Johnson & Johnson reported on Monday, November 9, that an investigational combination of pasritamig and JNJ-9401 produced deep PSA reductions in a Phase 1 study of advanced prostate cancer. The company said 11 of 15 patients at the recommended regimen achieved a PSA reduction of at least 50 percent, while seven patients recorded reductions of at least 90 percent.
The update adds that all seven patients with the deepest PSA reductions remained on treatment for more than six months without disease progression. No treatment-related adverse event of Grade 3 or higher was reported in the early analysis. Johnson & Johnson published the findings in its press release after presenting the data at the 2026 Society for Immunotherapy of Cancer meeting.
Small Study, Larger Development Step
The results concern patients with metastatic castration-resistant prostate cancer who had received a median of four prior lines of systemic therapy. The recommended regimen combines subcutaneous JNJ-9401 with intravenous pasritamig every six weeks after two initial weekly pasritamig doses.
The combination is moving into the Phase 3 KLK2-comPAS study. That trial will test whether adding JNJ-9401 to pasritamig improves outcomes in a larger patient population. The early response signal is relevant for Johnson & Johnson's oncology pipeline, but the small Phase 1 efficacy group leaves clinical benefit and safety subject to further evaluation.
Johnson & Johnson stock traded at 251.05 euros on Lang & Schwarz at 16:32 CET on Tuesday, November 10, 2026, 0.64 percent above the Xetra close of Monday, November 9, 2026. The Xetra reference close was 249.45 euros.
Johnson & Johnson stock at a glance
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: JNJ
- Home exchange: New York Stock Exchange
- Lang & Schwarz price: 251.05 euros at 16:32 CET on November 10, 2026
- Change versus Xetra close: 0.64 percent above 249.45 euros on November 9, 2026
Healthcare shares remain sensitive to clinical readouts, regulatory milestones and broader risk appetite. Follow the latest market reports for the wider market setting.
